Astellas, Partners Reach Settlement With Teva on Tarceva Patent

Astellas Pharma Inc. (4503) said subsidiary OSI Pharmaceuticals Inc. agreed with Teva Pharmaceutical Industries Ltd. (TEVA) to settle a pending patent- infringment lawsuit for the Tarceva lung-cancer drug. Genentech Inc. and Pfizer Inc. (PFE) were also part of the lawsuit filed against Teva.

Astellas didn’t disclose the details of the settlement in a statement from Astellas to the Tokyo Stock Exchange today.

To contact the editor responsible for this story: Gearoid Reidy at greidy1@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.